Should I buy or sell I-Mab stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMAB shares. View IMAB analyst ratings or view top-rated stocks .

What is I-Mab's stock price target for 2024?

4 equities research analysts have issued 1 year target prices for I-Mab's shares. Their IMAB share price targets range from $6.00 to $25.00. On average, they predict the company's share price to reach $12.25 in the next year. This suggests a possible upside of 580.6% from the stock's current price. View analysts price targets for IMAB or view top-rated stocks among Wall Street analysts .

How have IMAB shares performed in 2024?

I-Mab's stock was trading at $1.90 at the start of the year. Since then, IMAB shares have decreased by 5.3% and is now trading at $1.80. View the best growth stocks for 2024 here .

Are investors shorting I-Mab?

I-Mab saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,170,000 shares, an increase of 7.3% from the March 15th total of 1,090,000 shares. Based on an average daily volume of 436,300 shares, the days-to-cover ratio is currently 2.7 days. View I-Mab's Short Interest .

What ETF holds I-Mab's stock?

Invesco Nasdaq Future Gen 200 ETF holds 23,061 shares of IMAB stock, representing 0.58% of its portfolio.

What other stocks do shareholders of I-Mab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO) , Moderna (MRNA) , ServiceNow (NOW) , Novavax (NVAX) , Gilead Sciences (GILD) , Cisco Systems (CSCO) , Enterprise Products Partners (EPD) , G1 Therapeutics (GTHX) , Intel (INTC) and Johnson & Johnson (JNJ) .

I-Mab (IMAB) raised $100 million in an initial public offering (IPO) on Thursday, January 16th 2020. The company issued 7,400,000 shares at $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

How do I buy shares of I-Mab?

Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMAB

I-Mab (IMAB) Stock Price, News & Analysis

→ The Gold Grab of the Century (From Colonial Metals) (Ad)

Free IMAB Stock Alerts

$1.80

-0.01 (-0.55%)

(As of 04/26/2024 08:52 PM ET)

Compare

Today's Range: $1.80
▼
$1.83
50-Day Range: $1.57
▼
$1.90
52-Week Range: $1.16
▼
$3.45

Volume: 88,500 shs
Average Volume: 453,269 shs
Market Capitalization: $145.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.25

Get I-Mab alerts:

I-Mab MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 580.6% Upside
$12.25 Price Target
Short Interest: Healthy
1.61% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.97) to ($1.72) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.40 out of 5 stars

Medical Sector

485th out of 916 stocks

Pharmaceutical Preparations Industry

207th out of 416 stocks

3.5

Analyst's Opinion

Consensus Rating
I-Mab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
I-Mab has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.61% of the outstanding shares of I-Mab have been sold short.
Short Interest Ratio / Days to Cover
I-Mab has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in I-Mab has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
I-Mab does not currently pay a dividend.
Dividend Growth
I-Mab does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMAB.

1.1

News and Social Media Coverage

Search Interest
24 people have searched for IMAB on MarketBeat in the last 30 days. This is an increase of 140% compared to the previous 30 days.
MarketBeat Follows
1 people have added I-Mab to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, I-Mab insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 38.38% of the stock of I-Mab is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for I-Mab are expected to grow in the coming year, from ($1.97) to ($1.72) per share.
Price to Book Value per Share Ratio
I-Mab has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad WealthPress

It’s now possible to know the win rate of every trade… BEFORE you take it!

Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.

>> You can grab your FREE, laminated copies right here <<

About I-Mab Stock (NASDAQ:IMAB)

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

IMAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMAB Stock News Headlines

April 16, 2024 | msn.com

Omega Therapeutics CFO Joshua Reed to depart

April 12, 2024 | markets.businessinsider.com

I-MAB Buy Rating Justified by Strong Leadership and Promising Pipeline

April 29, 2024 | DTI (Ad)

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

April 5, 2024 | prnewswire.com

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

April 4, 2024 | investing.com

I-Mab completes divestiture of its Shanghai unit for $80 million

April 2, 2024 | uk.finance.yahoo.com

I-Mab Announces Closing of the Divestiture of Business Operations in China

April 2, 2024 | prnewswire.com

I-Mab Announces Closing of the Divestiture of Business Operations in China

March 18, 2024 | finance.yahoo.com

I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

April 29, 2024 | DTI (Ad)

A new way to collect income from stocks

March 14, 2024 | finance.yahoo.com

I-Mab Reports Full Year 2023 Financial Results and Business Update

February 22, 2024 | benzinga.com

I-MAB Stock (NASDAQ:IMAB), Short Interest Report

February 18, 2024 | seekingalpha.com

I-Mab: Trading Below Net Cash With Multiple Upside Options

February 7, 2024 | marketwatch.com

I-Mab to Divest Chinese Unit for Up to $80M

February 7, 2024 | msn.com

I-Mab to divest Chinese assets amid rising geopolitical tensions

February 7, 2024 | finance.yahoo.com

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

January 11, 2024 | msn.com

Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading

December 31, 2023 | uk.finance.yahoo.com

I-Mab (IMAB) interactive stock chart – Yahoo Finance

December 28, 2023 | benzinga.com

I-MAB Stock (NASDAQ:IMAB) Dividends: History, Yield and Dates

November 19, 2023 | finance.yahoo.com

Individual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%

November 6, 2023 | finance.yahoo.com

I-Mab Announces Participation at Jefferies and Piper Conferences in November

November 2, 2023 | msn.com

I-Mab gains FDA breakthrough tag for kidney disease therapy

November 2, 2023 | markets.businessinsider.com

I-Mab:Felzartamab Granted Breakthrough Therapy Designation By FDA For Primary Membranous Nephropathy

November 2, 2023 | finance.yahoo.com

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

November 1, 2023 | finance.yahoo.com

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

October 16, 2023 | finance.yahoo.com

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

October 10, 2023 | finance.yahoo.com

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

October 5, 2023 | insidermonkey.com

Ray Dalio on Potential US China War and Rise of China

See More Headlines

Receive IMAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/28/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMAB
CUSIP: N/A
CIK: 1778016
Web: www.i-mabbiopharma.com
Phone: 86-21-6057-8000
Fax: N/A
Employees: 228
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.25
High Stock Price Target: $25.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +580.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.67
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $3.89 million
Price / Sales: 37.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.93 per share
Price / Book: 0.61

Miscellaneous

Outstanding Shares: 80,700,000
Free Float: 62,867,000
Market Cap: $145.26 million
Optionable: Optionable
Beta: 1.11

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Raj Kannan (Age 60)
CEO & Director
Dr. Jerry Wang
Co-Founder & Chief Scientific Officer
Mr. Skelton Joseph
Chief Financial Officer
Mr. Tianyi Zhang
Vice President of Investor Relations
Mr. Cheng Li (Age 40)
Chief Legal Officer
Ms. Gigi Qi Feng (Age 43)
Chief Communications Officer
Dr. Weiming Tang Ph.D. (Age 58)
Executive VP of Global Business Development & Chief Business Officer
Dr. Fernando J. Salle´s Ph.D.
Senior VP and Head of U.S. & EU Business Development
Claire Xu
Head of US site
Dr. John Hayslip M.D. (Age 47)
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IMAB Stock Analysis - Frequently Asked Questions

Should I buy or sell I-Mab stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for I-Mab in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMAB shares.
View IMAB analyst ratings or view top-rated stocks.
What is I-Mab's stock price target for 2024?: 4 equities research analysts have issued 1 year target prices for I-Mab's shares. Their IMAB share price targets range from $6.00 to $25.00. On average, they predict the company's share price to reach $12.25 in the next year. This suggests a possible upside of 580.6% from the stock's current price.
View analysts price targets for IMAB or view top-rated stocks among Wall Street analysts.
How have IMAB shares performed in 2024?: I-Mab's stock was trading at $1.90 at the start of the year. Since then, IMAB shares have decreased by 5.3% and is now trading at $1.80.
View the best growth stocks for 2024 here.
Are investors shorting I-Mab?: I-Mab saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,170,000 shares, an increase of 7.3% from the March 15th total of 1,090,000 shares. Based on an average daily volume of 436,300 shares, the days-to-cover ratio is currently 2.7 days.
View I-Mab's Short Interest.

What ETF holds I-Mab's stock?: Invesco Nasdaq Future Gen 200 ETF holds 23,061 shares of IMAB stock, representing 0.58% of its portfolio.
What other stocks do shareholders of I-Mab own?: Based on aggregate information from My MarketBeat watchlists, some companies that other I-Mab investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), ServiceNow (NOW), Novavax (NVAX), Gilead Sciences (GILD), Cisco Systems (CSCO), Enterprise Products Partners (EPD), G1 Therapeutics (GTHX), Intel (INTC) and Johnson & Johnson (JNJ).
When did I-Mab IPO?: I-Mab (IMAB) raised $100 million in an initial public offering (IPO) on Thursday, January 16th 2020. The company issued 7,400,000 shares at $12.00-$15.00 per share. Jefferies and CICC served as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.
How do I buy shares of I-Mab?: Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMAB) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial